Zusammenfassung
Im Gegensatz zu früheren Annahmen konnte inzwischen klar belegt werden, daß sich das Immunsystem bereits spontan mit Tumoren auseinandersetzt. Beim Melanom, aber auch bei anderen soliden Tumoren und Leukämien können teilweise hochfrequente zytotoxische Effektor-T-Zellen im peripheren Blut nachgewiesen werden.Warum Tumoren dennoch häufig nicht vom Immunsystem zerstört werden, ist bislang unvollständig geklärt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Badros A, Barlogie B, Morris Ch (2001) High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97:2574–2579
Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854
Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18:245–273
Hsu FJ, Zheng X, Thompson CB et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52–58
Keilholz U, Conradt C, Legha SS et al (1998) Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 9:2921–2929
Keilholz U, Weber J, Finke JH et al (2002) Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138
Marchand M, van Baren N, Weynants P et al (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219–230
Mitchell MS, Darrah D, Yeung D et al (2002) Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20:1075–1086
Molldrem JJ, Kant S, Lu S et al (2002) Peptide vaccinationwith PR1 elicits active T cell immunity that induces cytogenetic remission in acute myelogenous leukemia. ASH Abstract Book 100:abstract 8
Parmiani G, Castelli C, Dalerba P et al (2002) Cancer immunotherapy with peptidebased vaccines: what have we achieved? Where are we going? Review. J Natl Cancer Inst 94:805–818
Peggs KS, Mackinnon S (2001) Cellular therapy: donor lymphocyte infusion. Curr Opin Hematol 8:349–354
Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Review. Nature 411:380–384
Slavin S (2001) Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol 2:491–498
Valmori D, Scheibenbogen C, Dutoit V et al (2002) Circulating tumor-reactive CD8+ T cells in melanoma patients contain a CD45RA+CCR7-effector subset exerting exvivo tumor-specific cytolytic activity. Cancer Res 62:1743–1750
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Keilholz, U., Bergmann, L., Schmitt, M., Scheibenbogen, C. (2006). Zelluläre Immuntherapie. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_42
Download citation
DOI: https://doi.org/10.1007/3-540-31303-6_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20657-6
Online ISBN: 978-3-540-31303-8
eBook Packages: Medicine (German Language)